Manatt Digital and Technology group and venture capital / emerging companies practice leader Lisa Suennen spoke with MedCity News on the FDA’s decision to approve Akili Interactive’s request to market its video game as a treatment for ADHD. In the article, Pavlovic discussed the importance of designing a control to minimize outside effects during a clinical trial, suggesting to “create a game or an app that isn’t expected to have a therapeutic effect but would replicate people spending time on a given activity.” Suennen added that the hardest part of the approval process will be securing reimbursement and distribution from insurance companies and physicians, saying, “[insurance companies] usually want you to do a study with them. They want evidence that’s more directly relevant before they go far with it.”
Read the article here.